Anti-cecam6 antibodies with reduced side-effects

dc.contributor.author	Carretero Coca, Rafael
dc.date.accessioned	2025-11-06T13:20:45Z
dc.date.available	2025-11-06T13:20:45Z
dc.date.issued	2023-03-09
dc.identifier.citation	WO2023031366A1: Anti-cecam6 antibodies with reduced side-effects	es_ES
dc.identifier.other	WO2023031366A1
dc.identifier.uri	https://hdl.handle.net/10481/107818
dc.description.abstract	The present invention provides antibodies, that bind to human CEACAM6 and are able to relieve CEACAM6-mediated immunosuppression, wherein said antibodies have reduced side-effects during treatment. The present invention further provides isolated nucleic acids encoding said antibodies and vectors comprising same, isolated cells expressing said antibodies, methods of producing said antibodies and pharmaceutical compositions and kits comprising said antibodies. Antibodies according to the present invention can be used to treat cancer and might be used to treat other disorders and conditions associated with the expression of the CEACAM6.	es_ES
dc.description.sponsorship	Deutsches Krebsforschungzentrum	es_ES
dc.language.iso	eng	es_ES
dc.publisher	WIPO/PCT	es_ES
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	CEACAM6	es_ES
dc.subject	Antibody	es_ES
dc.subject	Cancer	es_ES
dc.title	Anti-cecam6 antibodies with reduced side-effects	es_ES
dc.type	patent	es_ES
dc.rights.accessRights	open access	es_ES
dc.type.hasVersion	VoR	es_ES

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional